SALE
市場調查報告書

肝臟癌症治療藥的全球市場:癌症的各類型,各治療法,各設備,各年齡,各要因,各給藥途徑,各地區的預測和機會

Global Liver Cancer Therapeutics Market By Cancer Type, By Therapy, By Equipment, By Age, By Factors, By Route of Administration, By Region, Forecast & Opportunities, 2025

出版商 TechSci Research 商品編碼 934734
出版日期 內容資訊 英文 119 Pages
商品交期: 請詢問到貨日
價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

肝臟癌症治療藥的全球市場:癌症的各類型,各治療法,各設備,各年齡,各要因,各給藥途徑,各地區的預測和機會 Global Liver Cancer Therapeutics Market By Cancer Type, By Therapy, By Equipment, By Age, By Factors, By Route of Administration, By Region, Forecast & Opportunities, 2025
出版日期: 2020年05月01日內容資訊: 英文 119 Pages
簡介

肝臟癌症,是長期進行的癌症,初期幾乎沒有症狀,不過,隨著進展呈現食慾不振,腹上部的疼痛,噁心與嘔吐,皮膚變黃等症狀。根據世界癌症研究基金,肝臟癌症是世界第6大患者數的癌症。隨著全世界的高齡化進展等患者數也有增加趨勢,推動創新的治療藥和治療方法的研究開發,肝臟癌症治療藥的市場,以靜脈內注射的抗癌劑為中心,今後也將繼續踏實成長。

本報告提供全球肝癌症治療藥的市場調查,新型冠狀病毒感染疾病(COVID-19)對市場產生的影響,各地區市場展望,市場力學與趨勢,競爭情形和主要企業的簡介等資訊之外,再加上策略性建議。

目錄

第1章 產品概要

第2章 調查方法

第3章 COVID-19對全球肝癌症治療市場的影響

第4章 客戶的迴響

第5章 摘要整理

第6章 全球市場的展望

  • 市場規模與預測
    • 以金額為準
  • 市場佔有率與預測
    • 癌症的各類型(肝細胞癌症,膽管癌症,肝芽腫,血管肉瘤,肝轉移)
    • 各治療法(標靶治療,放射線治療,免疫療法,化療,射頻消融術,微波切除,栓塞術和化學栓塞術,手術)
    • 各設備(電腦放射成像,高頻設備,微波設備,超音波設備,MRI,醫療用線性加速器(線型加速器),輸液幫浦)
    • 各年齡(0∼18歲,18∼35歲,35∼50歲,50歲多)
    • 各要因(由於B型肝炎病毒和C型肝炎病毒的慢性感染疾病,肝硬化,遺傳性肝疾病,糖尿病,非酒精性脂肪肝病,對黃麴毒素的暴露,過度攝取酒精)
    • 各給藥途徑(口服,靜脈內,動脈內,腫瘤內,門靜脈內,脾臟內,膽管轄範圍內)
    • 各流通管道(醫院藥局,零售藥局,線上藥局)
    • 各企業(2019年)
    • 各地區
  • 市場魅力指數

第7章 亞太地區市場展望

  • 市場規模與預測
    • 以金額為準
  • 市場佔有率與預測
    • 癌症的各類型
    • 各治療法
    • 各設備
    • 各年齡
    • 各要因
    • 各給藥途徑
    • 各國
  • 亞太地區:各國分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

第8章 歐洲市場展望

  • 市場規模與預測
    • 以金額為準
  • 市場佔有率與預測
    • 癌症的各類型
    • 各治療法
    • 各設備
    • 各年齡
    • 各要因
    • 各給藥途徑
    • 各國
  • 歐洲:各國分析
    • 法國
    • 德國
    • 英國
    • 義大利
    • 西班牙

第9章 北美的肝癌症治療藥市場展望

  • 市場規模與預測
    • 以金額為準
  • 市場佔有率與預測
    • 癌症的各類型
    • 各治療法
    • 各設備
    • 各年齡
    • 各要因
    • 各給藥途徑
    • 各國
  • 北美:各國分析
    • 美國
    • 墨西哥
    • 加拿大

第10章 南美市場展望

  • 市場規模與預測
    • 以金額為準
  • 市場佔有率與預測
    • 癌症的各類型
    • 各治療法
    • 各設備
    • 各年齡
    • 各要因
    • 各給藥途徑
    • 各國
  • 南美:各國分析
    • 巴西
    • 阿根廷
    • 哥倫比亞

第11章 中東及非洲的肝癌治療藥市場展望

  • 市場規模與預測
    • 以金額為準
  • 市場佔有率與預測
    • 癌症的各類型
    • 各治療法
    • 各設備
    • 各年齡
    • 各要因
    • 各給藥途徑
    • 各國
  • 中東、非洲:各國分析
    • 南非
    • 沙烏地阿拉伯
    • UAE

第12章 市場力學

  • 促進促進因素
  • 課題

第13章 市場趨勢

第14章 競爭情形

  • 競爭情形的展望
  • 主要企業的簡介
    • Bayer AG
    • Alnylam Pharmaceuticals Inc.
    • F. Hoffmann-La Roche AG
    • Bristol-Myers Squibb Co
    • Eisai Co., Ltd.
    • Pfizer Inc.
    • Exelixis, Inc.
    • Merck & Co. Inc.
    • Celsion Corporation
    • ArQule Inc.
    • Johnson & Johnson
    • Novartis
    • Sanofi
    • Eli Lily
    • Perkin Elmer
    • Sunpharma
    • AbbVie
    • Amgen
    • AstraZeneca
    • Philips Healthcare

第15章 策略性建議

第16章 免責聲明

目錄
Product Code: 4667

As on date of publishing, this report will capture the impact assessment of COVID-19 on this market and the same will be considered in our market forecast model. Clients purchasing this report between April and June 2020 will be getting a 'free' updated market data excel sheet between July and September 2020 accounting for the impact of COVID-19 on the market in the current year 2020 and forecast.

Global liver cancer therapeutics market is expected to grow at a brisk CAGR during the forecast period. Major factors behind the growth of this market are rising cases of liver cancer globally, increasing awareness among people, growing aging population, and increasing funding by governments in research and development activities for cancer cure.

Liver cancer is a chronic and life-threatening disease which begins in cells of liver. Most of the liver cancer patients do not show the symptoms at early stages but in later stages, the common symptoms include loss of appetite, upper abdominal pain, nausea and vomiting and yellow discoloration of skin. According to World Cancer Research Fund, liver cancer is the sixth most common cancer across the globe. Therefore, scientists are working on developing more innovative drugs and therapies for liver cancer treatment. However, the market also faces some restrains. Expensive treatments as well as high cost in research and development might hamper the further growth of liver cancer therapeutics market.

The global liver cancer therapeutics market is segmented based on cancer type, therapy, equipment, age, factors, route of administration, distribution channel and region. Based on route of administration, the market is segmented into oral, intravenous, intra-arterial, intra-tumoral, intra-portal, intra-splenic and intra-biliary. The intravenous segment is anticipated to dominate the global liver cancer therapeutics market during the forecast period as it is most preferred route of administration for chemotherapy. Also, high osmolality drugs are administered through intravenous route, which makes it a preferred route of administration.

Major players operating in the global liver cancer therapeutics market include Bayer AG, Alnylam Pharmaceuticals Inc., F. Hoffmann-La Roche AG , Bristol-Myers Squibb Co, Eisai Co., Ltd. , Pfizer Inc., Exelixis, Inc., Merck & Co. Inc., Celsion Corporation , ArQule Inc., Johnson & Johnson, Novartis, Sanofi, Eli Lily, Perkin Elmer, Sunpharma, AbbVie, Amgen, AstraZeneca, Philips Healthcare and others.

Years considered for this report:

Historical Years: 2015-2018

Base Year: 2019

Estimated Year: 2020

Forecast Period: 2021-2025

Objective of the Study

  • To analyze and forecast the market size of global liver cancer therapeutics market.
  • To classify and forecast global liver cancer therapeutics market based on cancer type, therapy, equipment, age, factors, route of administration, distribution channel and region.
  • To identify drivers and challenges for global liver cancer therapeutics market.
  • To examine competitive developments such as expansions, new product launches, mergers & acquisitions, etc., in global liver cancer therapeutics market.
  • To conduct pricing analysis for global liver cancer therapeutics market.
  • To identify and analyze the profile of leading players operating in global liver cancer therapeutics market.

TechSci Research performed both primary as well as exhaustive secondary research for this study. Initially, TechSci Research sourced a list of manufacturers across the globe. Subsequently, TechSci Research conducted primary research surveys with the identified companies. While interviewing, the respondents were also enquired about their competitors. Through this technique, TechSci Research could include the manufacturers which could not be identified due to the limitations of secondary research. TechSci Research analyzed the manufacturers, distribution channels and presence of all major players across the globe.

TechSci Research calculated the market size of global liver cancer therapeutics market using a bottom-up approach, wherein data for various end-user segments was recorded and forecast for the future years. TechSci Research sourced these values from the industry experts and company representatives and externally validated through analyzing historical data of these product types and applications for getting an appropriate, overall market size. Various secondary sources such as company websites, news articles, press releases, company annual reports, investor presentations and financial reports were also studied by TechSci Research.

Key Target Audience

  • Liver cancer therapeutics manufacturers, suppliers, distributors and other stakeholders
  • Government bodies such as regulating authorities and policy makers
  • Organizations, forums and alliances related to liver cancer therapeutics
  • Market research and consulting firms

The study is useful in providing answers to several critical questions that are important for the industry stakeholders such as manufacturers, suppliers, partners, end users, etc., besides allowing them in strategizing investments and capitalizing on market opportunities.

Report Scope

In this report, global liver cancer therapeutics market has been segmented into following categories, in addition to the industry trends which have also been detailed below:

  • Market, By Cancer Type:

Hepatocellular Carcinoma

Cholangiocarcinoma

Hepatoblastoma

Angiosarcoma

Liver Metastasis

  • Market, By Therapy:

Targeted Therapy

Radiation Therapy

Immunotherapy

Chemotherapy

Radiofrequency Ablation

Microwave Ablation

Embolization & Chemoembolization

Surgery

  • Market, By Equipment:

Computed Radiography

Radiofrequency Equipment

Microwave Equipment

Ultrasound

Mri

Medical Linear Accelerator (Linac)

Infusion Pumps

  • Market, By Age:

0-18

18-35

35-50

50+

  • Market, By Factors:

Chronic Infection with HBV Or HCV

Cirrhosis

Inherited Liver Disease

Diabetes

Nonalcoholic Fatty Liver Disease

Exposure To Aflatoxins

Excessive Alcohol Consumption

  • Market, By Route of Administration:

Oral

Intravenous

Intra-Arterial

Intra-Tumoral

Intra-Portal

Intra-Splenic

Intra-Biliary

  • Market, By Distribution Channel:

Hospital Pharmacies

Retail Pharmacies

Online Pharmacies

  • Market, By Region:

North America

  • United States
  • Canada
  • Mexico

Europe

  • Germany
  • France
  • United Kingdom
  • Italy
  • Spain

Asia-Pacific

  • China
  • Japan
  • India
  • South Korea
  • Australia

Middle East & Africa

  • South Africa
  • Saudi Arabia
  • UAE

South America

  • Brazil
  • Argentina
  • Colombia

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in global liver cancer therapeutics market.

Available Customizations

With the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

2. Research Methodology

3. Impact of COVID-19 on Global Liver Cancer Therapeutics Market

4. Voice of Customer

5. Executive Summary

6. Global Liver Cancer Therapeutics Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Cancer Type (Hepatocellular Carcinoma, Cholangiocarcinoma, Hepatoblastoma, Angiosarcoma, Liver Metastasis)
    • 6.2.2. By Therapy (Targeted Therapy, Radiation Therapy, Immunotherapy, Chemotherapy, Radiofrequency Ablation, Microwave Ablation, Embolization & Chemoembolization, Surgery)
    • 6.2.3. By Equipment (Computed Radiography, Radiofrequency Equipment, Microwave Equipment, Ultrasound, Mri, Medical Linear Accelerator (Linac), Infusion Pumps)
    • 6.2.4. By Age (0-18, 18-35, 35-50, 50+)
    • 6.2.5. By Factors (Chronic Infection with HBV or HCV, Cirrhosis, Inherited Liver Disease, Diabetes, Nonalcoholic Fatty Liver Disease, Exposure To Aflatoxins, Excessive Alcohol Consumption)
    • 6.2.6. By Route of Administration (Oral, Intravenous, Intra-Arterial, Intra-Tumoral, Intra-Portal, Intra-Splenic, Intra-Biliary)
    • 6.2.7. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)
    • 6.2.8. By Company (2019)
    • 6.2.9. By Region
  • 6.3. Market Attractiveness Index

7. Asia-Pacific Liver Cancer Therapeutics Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Cancer Type
    • 7.2.2. By Therapy
    • 7.2.3. By Equipment
    • 7.2.4. By Age
    • 7.2.5. By Factors
    • 7.2.6. By Route of Administration
    • 7.2.7. By Country
  • 7.3. Asia-Pacific: Country Analysis
    • 7.3.1. China Liver Cancer Therapeutics Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Cancer Type
        • 7.3.1.2.2. By Therapy
        • 7.3.1.2.3. By Equipment
        • 7.3.1.2.4. By Age
        • 7.3.1.2.5. By Factors
        • 7.3.1.2.6. By Route of Administration
    • 7.3.2. India Liver Cancer Therapeutics Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Cancer Type
        • 7.3.2.2.2. By Therapy
        • 7.3.2.2.3. By Equipment
        • 7.3.2.2.4. By Age
        • 7.3.2.2.5. By Factors
        • 7.3.2.2.6. By Route of Administration
    • 7.3.3. Japan Liver Cancer Therapeutics Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Cancer Type
        • 7.3.3.2.2. By Therapy
        • 7.3.3.2.3. By Equipment
        • 7.3.3.2.4. By Age
        • 7.3.3.2.5. By Factors
        • 7.3.3.2.6. By Route of Administration
    • 7.3.4. South Korea Liver Cancer Therapeutics Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Cancer Type
        • 7.3.4.2.2. By Therapy
        • 7.3.4.2.3. By Equipment
        • 7.3.4.2.4. By Age
        • 7.3.4.2.5. By Factors
        • 7.3.4.2.6. By Route of Administration
    • 7.3.5. Australia Liver Cancer Therapeutics Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Cancer Type
        • 7.3.5.2.2. By Therapy
        • 7.3.5.2.3. By Equipment
        • 7.3.5.2.4. By Age
        • 7.3.5.2.5. By Factors
        • 7.3.5.2.6. By Route of Administration

8. Europe Liver Cancer Therapeutics Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Cancer Type
    • 8.2.2. By Therapy
    • 8.2.3. By Equipment
    • 8.2.4. By Age
    • 8.2.5. By Factors
    • 8.2.6. By Route of Administration
    • 8.2.7. By Country
  • 8.3. Europe: Country Analysis
    • 8.3.1. France Liver Cancer Therapeutics Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Cancer Type
        • 8.3.1.2.2. By Therapy
        • 8.3.1.2.3. By Equipment
        • 8.3.1.2.4. By Age
        • 8.3.1.2.5. By Factors
        • 8.3.1.2.6. By Route of Administration
    • 8.3.2. Germany Liver Cancer Therapeutics Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Cancer Type
        • 8.3.2.2.2. By Therapy
        • 8.3.2.2.3. By Equipment
        • 8.3.2.2.4. By Age
        • 8.3.2.2.5. By Factors
        • 8.3.2.2.6. By Route of Administration
    • 8.3.3. United Kingdom Liver Cancer Therapeutics Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Cancer Type
        • 8.3.3.2.2. By Therapy
        • 8.3.3.2.3. By Equipment
        • 8.3.3.2.4. By Age
        • 8.3.3.2.5. By Factors
        • 8.3.3.2.6. By Route of Administration
    • 8.3.4. Italy Liver Cancer Therapeutics Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Cancer Type
        • 8.3.4.2.2. By Therapy
        • 8.3.4.2.3. By Equipment
        • 8.3.4.2.4. By Age
        • 8.3.4.2.5. By Factors
        • 8.3.4.2.6. By Route of Administration
    • 8.3.5. Spain Liver Cancer Therapeutics Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Cancer Type
        • 8.3.5.2.2. By Therapy
        • 8.3.5.2.3. By Equipment
        • 8.3.5.2.4. By Age
        • 8.3.5.2.5. By Factors
        • 8.3.5.2.6. By Route of Administration

9. North America Liver Cancer Therapeutics Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Cancer Type
    • 9.2.2. By Therapy
    • 9.2.3. By Equipment
    • 9.2.4. By Age
    • 9.2.5. By Factors
    • 9.2.6. By Route of Administration
    • 9.2.7. By Country
  • 9.3. North America: Country Analysis
    • 9.3.1. United States Liver Cancer Therapeutics Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Cancer Type
        • 9.3.1.2.2. By Therapy
        • 9.3.1.2.3. By Equipment
        • 9.3.1.2.4. By Age
        • 9.3.1.2.5. By Factors
        • 9.3.1.2.6. By Route of Administration
    • 9.3.2. Mexico Liver Cancer Therapeutics Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Cancer Type
        • 9.3.2.2.2. By Therapy
        • 9.3.2.2.3. By Equipment
        • 9.3.2.2.4. By Age
        • 9.3.2.2.5. By Factors
        • 9.3.2.2.6. By Route of Administration
    • 9.3.3. Canada Liver Cancer Therapeutics Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Cancer Type
        • 9.3.3.2.2. By Therapy
        • 9.3.3.2.3. By Equipment
        • 9.3.3.2.4. By Age
        • 9.3.3.2.5. By Factors
        • 9.3.3.2.6. By Route of Administration

10. South America Liver Cancer Therapeutics Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Cancer Type
    • 10.2.2. By Therapy
    • 10.2.3. By Equipment
    • 10.2.4. By Age
    • 10.2.5. By Factors
    • 10.2.6. By Route of Administration
    • 10.2.7. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Liver Cancer Therapeutics Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Cancer Type
        • 10.3.1.2.2. By Therapy
        • 10.3.1.2.3. By Equipment
        • 10.3.1.2.4. By Age
        • 10.3.1.2.5. By Factors
        • 10.3.1.2.6. By Route of Administration
    • 10.3.2. Argentina Liver Cancer Therapeutics Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Cancer Type
        • 10.3.2.2.2. By Therapy
        • 10.3.2.2.3. By Equipment
        • 10.3.2.2.4. By Age
        • 10.3.2.2.5. By Factors
        • 10.3.2.2.6. By Route of Administration
    • 10.3.3. Colombia Liver Cancer Therapeutics Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Cancer Type
        • 10.3.3.2.2. By Therapy
        • 10.3.3.2.3. By Equipment
        • 10.3.3.2.4. By Age
        • 10.3.3.2.5. By Factors
        • 10.3.3.2.6. By Route of Administration

11. Middle East and Africa Liver Cancer Therapeutics Market Outlook

  • 11.1. Market Size & Forecast
    • 11.1.1. By Value
  • 11.2. Market Share & Forecast
    • 11.2.1. By Cancer Type
    • 11.2.2. By Therapy
    • 11.2.3. By Equipment
    • 11.2.4. By Age
    • 11.2.5. By Factors
    • 11.2.6. By Route of Administration
    • 11.2.7. By Country
  • 11.3. MEA: Country Analysis
    • 11.3.1. South Africa Liver Cancer Therapeutics Market Outlook
      • 11.3.1.1. Market Size & Forecast
        • 11.3.1.1.1. By Value
      • 11.3.1.2. Market Share & Forecast
        • 11.3.1.2.1. By Cancer Type
        • 11.3.1.2.2. By Therapy
        • 11.3.1.2.3. By Equipment
        • 11.3.1.2.4. By Age
        • 11.3.1.2.5. By Factors
        • 11.3.1.2.6. By Route of Administration
    • 11.3.2. Saudi Arabia Liver Cancer Therapeutics Market Outlook
      • 11.3.2.1. Market Size & Forecast
        • 11.3.2.1.1. By Value
      • 11.3.2.2. Market Share & Forecast
        • 11.3.2.2.1. By Cancer Type
        • 11.3.2.2.2. By Therapy
        • 11.3.2.2.3. By Equipment
        • 11.3.2.2.4. By Age
        • 11.3.2.2.5. By Factors
        • 11.3.2.2.6. By Route of Administration
    • 11.3.3. UAE Liver Cancer Therapeutics Market Outlook
      • 11.3.3.1. Market Size & Forecast
        • 11.3.3.1.1. By Value
      • 11.3.3.2. Market Share & Forecast
        • 11.3.3.2.1. By Cancer Type
        • 11.3.3.2.2. By Therapy
        • 11.3.3.2.3. By Equipment
        • 11.3.3.2.4. By Age
        • 11.3.3.2.5. By Factors
        • 11.3.3.2.6. By Route of Administration

12. Market Dynamics

  • 12.1. Drivers
  • 12.2. Challenges

13. Market Trends & Developments

14. Competitive Landscape

  • 14.1. Competition Outlook
  • 14.2. Players Profiled (Leading Companies)
    • 14.2.1. Bayer AG
    • 14.2.2. Alnylam Pharmaceuticals Inc.
    • 14.2.3. F. Hoffmann-La Roche AG
    • 14.2.4. Bristol-Myers Squibb Co
    • 14.2.5. Eisai Co., Ltd.
    • 14.2.6. Pfizer Inc.
    • 14.2.7. Exelixis, Inc.
    • 14.2.8. Merck & Co. Inc.
    • 14.2.9. Celsion Corporation
    • 14.2.10. ArQule Inc.
    • 14.2.11. Johnson & Johnson
    • 14.2.12. Novartis
    • 14.2.13. Sanofi
    • 14.2.14. Eli Lily
    • 14.2.15. Perkin Elmer
    • 14.2.16. Sunpharma
    • 14.2.17. AbbVie
    • 14.2.18. Amgen
    • 14.2.19. AstraZeneca
    • 14.2.20. Philips Healthcare

15. Strategic Recommendations

16. About Us & Disclaimer